Zimbabwe has rejected a substantial American healthcare agreement worth $367m (272 million pounds) spanning five years due to the United States' request for sensitive data.
This move came to light after a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the deal was "unbalanced".
An official representative has since clarified that the US was demanding access to biological samples for research and commercial gain while was unwilling to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued negotiations to find a deal suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
This rejection follows a comparable situation in Kenya, where a high court halted a related deal with the US after concerns were raised about the safety of citizens' health data.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to boost transparency and responsibility.
According to statements, 16 African countries have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information indefinitely, with no corresponding assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our people if a new disease outbreak emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting frameworks already established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This system is designed to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future collaboration could be arranged in a way that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but urged that negotiations should continue since much of the nation's HIV programmes relied on international support.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," the group said.
The situation underscores the continuing tensions between receiving crucial international aid and safeguarding local interests in an ever more data-driven world.